Kymera Therapeutics (NASDAQ:KYMR) Sets New 1-Year Low at $18.42

Kymera Therapeutics, Inc. (NASDAQ:KYMR) hit a new 52-week low during trading on Monday . The company traded as low as $18.42 and last traded at $18.88, with a volume of 103377 shares changing hands. The stock had previously closed at $18.94.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of analyst reports. Morgan Stanley lowered their price objective on Kymera Therapeutics from $39.00 to $37.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 29th. Stifel Nicolaus increased their price objective on Kymera Therapeutics from $48.00 to $52.00 and gave the company a “buy” rating in a report on Monday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 target price on shares of Kymera Therapeutics in a report on Friday, August 4th. Truist Financial started coverage on Kymera Therapeutics in a report on Friday, June 30th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Credit Suisse Group raised their target price on Kymera Therapeutics from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $48.10.

Kymera Therapeutics Trading Up 0.7 %

The company has a market cap of $1.06 billion, a price-to-earnings ratio of -6.89 and a beta of 1.51. The company has a fifty day moving average price of $21.01 and a two-hundred day moving average price of $26.38.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.03. The company had revenue of $16.51 million for the quarter, compared to analyst estimates of $13.93 million. Kymera Therapeutics had a negative return on equity of 33.17% and a negative net margin of 305.01%. Kymera Therapeutics’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.78) EPS. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KYMR. Dark Forest Capital Management LP bought a new position in Kymera Therapeutics in the 1st quarter valued at $238,000. Simplify Asset Management Inc. acquired a new position in Kymera Therapeutics in the first quarter valued at about $312,000. Swiss National Bank grew its stake in Kymera Therapeutics by 2.1% in the fourth quarter. Swiss National Bank now owns 81,400 shares of the company’s stock valued at $2,032,000 after acquiring an additional 1,700 shares during the period. Artal Group S.A. lifted its holdings in shares of Kymera Therapeutics by 33.3% in the fourth quarter. Artal Group S.A. now owns 2,000,000 shares of the company’s stock valued at $49,920,000 after purchasing an additional 500,000 shares in the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of Kymera Therapeutics by 2.3% in the first quarter. California State Teachers Retirement System now owns 45,387 shares of the company’s stock valued at $1,345,000 after purchasing an additional 1,006 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.